SELLAS Life Sciences Group, Inc. (SLS) is listed on NASDAQ in Pharmaceutical Stocks. It is $13.17, -13.45%, with a $2.7B market cap. RSI is 50.0, neutral. The latest reported quarter missed estimates. Insiders were net buyers across the listed trades.
Technical Analysis
RSI (14) 50.0 Neutral
Market Cap $2.7B
Volume 5.2M
Fundamentals — 10-Q Q2 2026
Revenue $0
Net Income $-18.0M
EPS $-0.10
P/E Ratio -131.6x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Kalin Katherine Bach | Director | Buy | 63,400 | $1.59 | $100,806 | 2025 Nov 19 |
| Van Nostrand Robert L | Director | Buy | 10,000 | $1.48 | $14,800 | 2025 Jun 12 |
| Wasman Jane | Director | Buy | 20,000 | $1.69 | $33,800 | 2025 May 30 |
| Kalin Katherine Bach | Director | Buy | 20,000 | $1.80 | $36,000 | 2025 May 22 |
| Stergiou Angelos M. | President and CEO | Sell | 6,494 | $2.61 | $16,949 | 2022 Dec 5 |
| Burns John Thomas | Senior VP, Finance & CAO | Sell | 1,159 | $2.59 | $3,002 | 2022 Dec 5 |
| Wood Barbara A | EVP, Gen. Counsel, Corp. Sec. | Sell | 2,153 | $2.59 | $5,576 | 2022 Dec 5 |
| Burns John Thomas | VP, Finance & Corp Controller | Sell | 231 | $6.27 | $1,448 | 2021 Dec 2 |
| Stergiou Angelos M. | President and CEO | Sell | 2,120 | $6.25 | $13,250 | 2021 Dec 2 |
| Wood Barbara A | EVP, Gen. Counsel, Corp. Sec. | Sell | 847 | $6.25 | $5,294 | 2021 Dec 2 |
| Stergiou Angelos M. | President and CEO | Sell | 23,277 | $1.25 | $29,096 | 2018 Dec 31 |
| Lewis Stephen R JR | Director | Buy | 1,000 | $5.58 | $5,580 | 2009 Jul 7 |
| Kraska Stanley J Jr | Insider | Buy | 2,000 | $4.81 | $9,620 | 2009 Feb 13 |
| Kraska Stanley J Jr | Insider | Buy | 1,000 | $6.24 | $6,240 | 2008 Oct 24 |
| Kraska Stanley J Jr | Insider | Buy | 1,000 | $9.43 | $9,430 | 2008 Oct 2 |
| Morris William C | Director | Buy | 8,600 | $18.30 | $157,347 | 2008 Sep 21 |
| Galvin John R | Director | Buy | 538 | $18.74 | $10,082 | 2007 Sep 28 |
| Shafer Robert L | Director | Buy | 1,000 | $18.23 | $18,230 | 2007 Sep 27 |
| Richie Leroy C | Director | Buy | 500 | $18.26 | $9,130 | 2007 Sep 27 |
| Maher John F | Director | Buy | 1,000 | $18.09 | $18,090 | 2007 Sep 26 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $20.85 | 65.2 | $2.2B |
| | $60.85 | 58.2 | $26.8B |
| | $34.70 | 44.3 | $25.1B |
| | $50.83 | 49.4 | -- |
Take SLS further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put SLS in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when SELLAS Life Sciences Group, Inc. next reports.
Set alerts on SLS
Get notified when SELLAS Life Sciences Group, Inc. hits your price targets or technical conditions are met.
Get Started Free